The brain uptake of biotherapeutics for brain diseases is hindered by the blood-brain barrier (BBB). The BBB selectively regulates the transport of large molecules into the brain and thereby maintains brain homeostasis. Receptor-mediated transcytosis (RMT) is one mechanism to deliver essential proteins into the brain parenchyma. Receptors expressed in the brain endothelial cells have been explored to ferry therapeutic antibodies across the BBB in bifunctional antibody formats. In this study, we generated and characterized monoclonal antibodies (mAbs) binding to the basigin receptor, which recently has been proposed as a target for RMT across the BBB. Antibody binding properties such as affinity have been demonstrated to be important factors for transcytosis capability and efficiency. Nevertheless, studies of basigin mAb properties' effect on RMT are limited. Here we characterize different basigin mAbs for their ability to associate with and subsequently internalize human brain endothelial cells. The mAbs were profiled to determine whether receptor binding epitope and affinity affected receptor-mediated uptake efficiency. By competitive epitope binning studies, basigin mAbs were categorized into five epitope bins. mAbs from three of the epitope bins demonstrated properties required for RMT candidates judged by binding characteristics and their superior level of internalization in human brain endothelial cells. Antibodies as therapeutic modalities are highly attractive due to their target specificity, long serum half-life, mechanism of actions, and limited off-target effects compared to small molecules and peptides. During the past decades, huge efforts have been made to optimize the delivery of biotherapeutics across the blood-brain barrier (BBB), which is a major limiting factor for successful antibody treatment of central nervous system-associated disorders. Systemic administration of antibodies results in low brain exposure of < 1% of the injected dose 1,2. The low permeability is due to the efficient tight junctions of the brain endothelial cells that form the front line of the BBB, preventing paracellular diffusion of large molecules into the brain. Most of the research effort has been focusing on enhancing transcellular transport as a non-invasive option. The most promising brain delivery strategy of antibodies relies on utilizing endogenous transport mechanisms, such as receptor-mediated transcytosis (RMT), by receptors present at the surface of brain endothelial cells to bypass the BBB. The transferrin receptor 1 (TfR1) has been explored extensively as a target for RMT, and in 1987 Fishman et al. 3 succeeded in enhancing brain exposure of antibodies specific for the TfR1. Since then, there has been an increasing interest in developing receptor-mediated drug delivery platforms to enhance brain uptake of central nervous system biotherapeutics. Targeting the TfR1 using antibodies with retained Fc effector led to safety liabilities such as a reduction in circulating reticulocytes, microglial activation, and as...